NEW YORK--(BUSINESS WIRE)--
Ophthotech Corporation (Nasdaq:OPHT) today announced that its fourth
quarter and year ended December 31, 2014 financial results will be
released on Monday, February 23, 2015. Following the announcement,
Ophthotech's management will host a live conference call and webcast at
5:00 p.m. Eastern Time to discuss the Company's financial results and
provide a general business update.
Pravin Dugel, M.D., Managing Partner of Retinal Consultants of Arizona
and Founding Member of the Spectra Eye Institute, will discuss initial
Fovista® data from his Investigator Sponsored Trial that was
featured at the 12th Annual Bascom-Palmer Eye Institute
Angiogenesis, Exudation, and Degeneration Meeting in Miami, Florida that
took place on February 7, 2015.
To participate in this conference call, dial 888-397-5352 (USA) or
719-325-2428 (International), passcode 5289090. A live, listen-only
audio web cast of the conference call can be accessed on the Investor
Relations section of the Ophthotech website at: www.ophthotech.com.
A replay will be available approximately two hours following the live
call for two weeks. The replay number is 888-203-1112 (USA Toll Free),
passcode 5289090. The audio webcast can be accessed at: www.ophthotech.com.
About Ophthotech Corporation
Ophthotech is a biopharmaceutical company specializing in the
development of novel therapeutics to treat diseases of the eye, with a
focus on developing innovative therapies for age-related macular
degeneration (AMD). Ophthotech's most advanced product candidate, Fovista®
anti-PDGF therapy, is in Phase 3 clinical trials for use in combination
with anti-VEGF drugs that represent the current standard of care for the
treatment of wet AMD. Ophthotech's second product candidate, Zimura™, an
inhibitor of complement factor C5, is being developed for the treatment
of geographic atrophy (a form of dry AMD) and, in combination with
anti-VEGF therapy and, potentially Fovista®, for the
treatment of wet AMD. For more information, please visit www.ophthotech.com.
Any statements in this press release about Ophthotech's future
expectations, plans and prospects constitute forward-looking statements
for purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Any forward-looking statements represent
Ophthotech's views only as of the date of this press release. Ophthotech
anticipates that subsequent events and developments will cause its views
to change. While Ophthotech may elect to update these forward-looking
statements at some point in the future, Ophthotech specifically
disclaims any obligation to do so.
Vice President, Investor Relations and Corporate
LLC on behalf of Ophthotech Corporation
Jarrod Aldom, 973-442-1555
Source: Ophthotech Corporation
News Provided by Acquire Media